Total Payments
$15,643
2024 Payments
$444.44
Companies
29
Transactions
173
Medicare Patients
953
Medicare Billing
$145,091
Payment Breakdown by Category
Food & Beverage$14,915 (95.3%)
Consulting$600.00 (3.8%)
Education$127.56 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $14,915 | 163 | 95.3% |
| Consulting Fee | $600.00 | 4 | 3.8% |
| Education | $127.56 | 6 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $3,240 | 40 | $0 (2023) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $1,889 | 18 | $0 (2021) |
| Teva Pharmaceuticals USA, Inc. | $1,449 | 15 | $0 (2021) |
| Sunovion Pharmaceuticals Inc. | $1,327 | 12 | $0 (2019) |
| Horizon Therapeutics plc | $911.81 | 10 | $0 (2023) |
| UCB, Inc. | $733.72 | 9 | $0 (2022) |
| GENZYME CORPORATION | $693.79 | 7 | $0 (2021) |
| Eisai Inc. | $662.19 | 7 | $0 (2024) |
| EMD Serono, Inc. | $642.57 | 7 | $0 (2023) |
| ACADIA Pharmaceuticals Inc | $640.72 | 9 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $444.44 | 5 | Eisai Inc. ($240.30) |
| 2023 | $1,097 | 11 | Biogen, Inc. ($333.01) |
| 2022 | $1,284 | 14 | Horizon Therapeutics plc ($511.14) |
| 2021 | $2,029 | 22 | NOVARTIS PHARMACEUTICALS CORPORATION ($544.53) |
| 2020 | $698.71 | 7 | Novartis Pharmaceuticals Corporation ($241.53) |
| 2019 | $3,609 | 37 | Biogen, Inc. ($803.34) |
| 2018 | $3,028 | 39 | Sunovion Pharmaceuticals Inc. ($766.88) |
| 2017 | $3,453 | 38 | Teva Pharmaceuticals USA, Inc. ($710.33) |
All Payment Transactions
173 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/01/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $59.55 | General |
| Category: Inflammation/Rare Disease | ||||||
| 06/11/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $123.51 | General |
| Category: Neurology | ||||||
| 05/23/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $19.59 | General |
| Category: Inflammation/Rare Disease | ||||||
| 04/15/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Neuroscience | ||||||
| 03/07/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $116.79 | General |
| Category: Neurology | ||||||
| 11/14/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $99.02 | General |
| Category: UPLIZNA | ||||||
| 10/11/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/04/2023 | EMD Serono, Inc. | MAVENCLAD (Drug) | Food and Beverage | Cash or cash equivalent | $121.82 | General |
| Category: Neurology | ||||||
| 08/14/2023 | Biogen, Inc. | Tysabri (Biological) | Food and Beverage | In-kind items and services | $49.73 | General |
| Category: Neurology | ||||||
| 08/14/2023 | Biogen, Inc. | Tysabri (Biological) | Food and Beverage | In-kind items and services | $45.45 | General |
| Category: Neurology | ||||||
| 07/26/2023 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $124.54 | General |
| Category: Immunology | ||||||
| 05/31/2023 | Biogen, Inc. | TYSABRI (Biological) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: Neurology | ||||||
| 05/23/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $113.08 | General |
| Category: UPLIZNA | ||||||
| 02/08/2023 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $87.83 | General |
| Category: Neurology | ||||||
| 02/02/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $107.07 | General |
| Category: UPLIZNA | ||||||
| 01/10/2023 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $73.43 | General |
| Category: Immunology | ||||||
| 12/15/2022 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $120.60 | General |
| Category: UPLIZNA | ||||||
| 12/14/2022 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $82.49 | General |
| Category: Neurology | ||||||
| 12/13/2022 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $119.81 | General |
| Category: UPLIZNA | ||||||
| 10/27/2022 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $68.70 | General |
| Category: Neurology | ||||||
| 08/25/2022 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Food and Beverage | In-kind items and services | $118.56 | General |
| Category: Rare Disease | ||||||
| 07/28/2022 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $112.26 | General |
| Category: UPLIZNA | ||||||
| 06/14/2022 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $102.02 | General |
| 04/16/2022 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $46.68 | General |
| Category: UPLIZNA | ||||||
| 03/31/2022 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $111.79 | General |
| Category: UPLIZNA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 199 | 308 | $55,210 | $31,784 |
| 2022 | 5 | 252 | 354 | $63,330 | $36,188 |
| 2021 | 5 | 265 | 386 | $69,440 | $42,060 |
| 2020 | 4 | 237 | 333 | $67,175 | $35,059 |
Total Patients
953
Total Services
1,381
Medicare Billing
$145,091
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 92 | 178 | $35,600 | $22,367 | 62.8% |
| 96116 | Exam of neurobehavioral status, first hour | Office | 2023 | 36 | 47 | $6,580 | $3,249 | 49.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $7,130 | $3,121 | 43.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 24 | 29 | $4,350 | $2,317 | 53.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 24 | 31 | $1,550 | $729.34 | 47.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 105 | 180 | $36,000 | $22,077 | 61.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 42 | 42 | $13,020 | $6,490 | 49.8% |
| 96116 | Exam of neurobehavioral status, first hour | Office | 2022 | 39 | 49 | $6,860 | $3,505 | 51.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 28 | 33 | $4,950 | $2,835 | 57.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 38 | 50 | $2,500 | $1,281 | 51.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 121 | 223 | $44,550 | $28,307 | 63.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 34 | 34 | $10,440 | $5,791 | 55.5% |
| 96116 | Neurobehavioral status examination by qualified health care professional with interpretation and report, first 60 minutes | Office | 2021 | 49 | 60 | $8,400 | $4,448 | 52.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 23 | 26 | $3,900 | $2,389 | 61.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 38 | 43 | $2,150 | $1,126 | 52.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 121 | 209 | $41,775 | $21,816 | 52.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 46 | 46 | $14,160 | $6,442 | 45.5% |
| 96116 | Neurobehavioral status examination by qualified health care professional with interpretation and report, first 60 minutes | Office | 2020 | 39 | 46 | $6,440 | $3,540 | 55.0% |
| 99354 | Prolonged office or other outpatient service first hour | Office | 2020 | 31 | 32 | $4,800 | $3,261 | 67.9% |
About Dr. John Kilian, M.D
Dr. John Kilian, M.D is a Specialist healthcare provider based in Tempe, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053352260.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Kilian, M.D has received a total of $15,643 in payments from pharmaceutical and medical device companies, with $444.44 received in 2024. These payments were reported across 173 transactions from 29 companies. The most common payment nature is "Food and Beverage" ($14,915).
As a Medicare-enrolled provider, Kilian has provided services to 953 Medicare beneficiaries, totaling 1,381 services with total Medicare billing of $145,091. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Tempe, AZ
- Active Since 06/09/2006
- Last Updated 01/30/2008
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1053352260
Products in Payments
- TYSABRI (Biological) $1,754
- APTIOM (Drug) $1,327
- UPLIZNA (Drug) $911.81
- TECFIDERA (Drug) $789.96
- NUPLAZID (Drug) $640.72
- COPAXONE (Drug) $591.12
- MAYZENT (Drug) $549.51
- KESIMPTA (Drug) $544.53
- AJOVY (Drug) $446.56
- Fycompa (Drug) $421.89
- Briviact (Drug) $399.64
- AUBAGIO (Drug) $338.86
- ZEPOSIA (Drug) $322.33
- AUSTEDO (Drug) $304.92
- GILENYA (Drug) $270.13
- Aimovig (Biological) $246.84
- Leqembi (Drug) $240.30
- UBRELVY (Drug) $240.06
- Neupro (Drug) $234.72
- VUMERITY (Drug) $212.51
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Tempe
Dr. Salaheddine Tomeh, Md, MD
Specialist — Payments: $158.39
Specialist $158.39
Dr. Charles Breed, Md, MD
Specialist — Payments: $122.96
Specialist $122.96
Dr. Hwa Ing Kang, M.d, M.D
Specialist — Payments: $15.45
Specialist $15.45
Gordon Genta, M.d, M.D
Specialist
Specialist
Mr. John Andreson, Atc, ATC
Specialist
Specialist
Katie Strasser, Atc, Lat, ATC, LAT
Specialist
Specialist